tbuckley/cabot-search huggingface dataset:
Profibrotic function of pulmonary group 2 innate lymphoid cells is controlled by regnase-1
Authors: Yoshinari Nakatsuka, Ai Yaku, Tomohiro Handa, Alexis Vandenbon, Yuki Hikichi, Yasutaka Motomura, Ayuko Sato, Masanori Yoshinaga, Kiminobu Tanizawa, Kizuku Watanabe, Toyohiro Hirai, Kazuo Chin, Yutaka Suzuki, Takuya Uehata, Takashi Mino, Tohru Tsujimura, Kazuyo Moro, Osamu Takeuchi
Journal: European Respiratory Journal (2020)

Regnase-1 is an RNase critical for post-transcriptional control of pulmonary immune homeostasis in mice by degrading immune-related mRNAs. However, little is known about the cell types Regnase-1 controls in the lung, and its relevance to human pulmonary diseases. Regnase-1-dependent changes in lung immune cell types were examined by a competitive bone marrow transfer mouse model, and group 2 innate lymphoid cells (ILC2s) were identified. Then the associations between Regnase-1 in ILC2s and human diseases were investigated by transcriptome analysis and a bleomycin-induced pulmonary fibrosis mouse model. The clinical significance of Regnase-1 in ILC2s was further assessed using patient-derived cells. Regnase-1 -deficiency resulted in the spontaneous proliferation and activation of ILC2s in the lung. Intriguingly, genes associated with pulmonary fibrosis were highly upregulated in Regnase-1 -deficient ILC2s compared with wild-type, and supplementation of Regnase-1 -deficient ILC2s augmented bleomycin-induced pulmonary fibrosis in mice. Regnase-1 suppresses mRNAs encoding transcription factors Gata3 and Egr1 , which are potent to regulate fibrosis-associated genes. Clinically, Regnase-1 protein levels in ILC2 negatively correlated with the ILC2 population in bronchoalveolar lavage fluid. Furthermore, idiopathic pulmonary fibrosis (IPF) patients with ILC2s &gt;1500 cells·mL −1 peripheral blood exhibited poorer prognosis than patients with lower numbers, implying the contribution of Regnase-1 in ILC2s for the progression of IPF. Collectively, Regnase-1 was identified as a critical post-transcriptional regulator of the profibrotic function of ILC2s both in mouse and human, suggesting that Regnase-1 may be a novel therapeutic target for IPF.
1001P PD1midKLRG1+Tbethigh effector memory T in the peripheral blood correlates with tumor response to combined therapy with lenvatinib and anti-PD-1 antibodies in unresectable hepatocellular carcinoma
Authors: H. Sun, C. Huang, X. Zhu, Y. Shen, N. Ge, Y. Chen, C. Tan, J. Zhou, J. Fan
Journal: Annals of Oncology (2020)
578P Interim analysis of a phase II study of SHR-1210 combined with neoadjuvant chemoradiation in patients with locally advanced proximal stomach adenocarcinoma (Neo-PLANET)
Authors: X. Wang, Y. Wang, Z. Tang, Y. Yu, Y. Cui, C. Tang, J. Sun, Q. Zhang, Y. Ji, G. Ma, Z. Shen, F. Liu, K. Shen, T. Liu, Y. Sun
Journal: Annals of Oncology (2020)
720P Randomised phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen in anti-angiogenic naïve patients with metastatic renal cell carcinoma (mRCC): Interim analysis (IA) of SURF study
Authors: A. Thiery-Vuillemin, G. Gravis, F. Constans Schlurmann, E. Bompas, F. Rolland, M. Gross-Goupil, Y.A. Vano, A. Guillot, P. Barthélémy, C. Joly, M. Laramas, L.M. Dourthe, T. Maurina, H. Gauthier Petithuguenin, K. Taillandy, A. Meurisse, D. Vernerey, L. Albiges
Journal: Annals of Oncology (2020)
1007P cfDNA and ctDNA variations are predictive of disease progression to conventional transarterial chemoembolization (cTACE) in patients with hepatocellular carcinoma (HCC)
Authors: D. Sefrioui, V. Verdier, C. Savoye-Collet, L. Beaussire, S. Ghomadi, A. Gangloff, O. Goria, G. Riachi, H. Montialoux, L. Schwarz, J-J. Tuech, T. Frebourg, P. Michel, N. Sarafan Vasseur, F. Di Fiore
Journal: Annals of Oncology (2020)
244P Breast cancer in young women (BCYW): Real world data to fill the gap and find the needs
Authors: M. Blanco Clemente, B. Núñez García, J. Sánchez Gonzalez, M. Méndez García, C. Alfaro Autor, A.M. Morito Aguilar, G. Visedo Ceballos, R. Aguado Noya, J.R. Castelló Fortet, F. de Borja Caballero, M. López Valcárcel, M.S. Carmona Rodríguez, M. Provencio Pulla, B. Cantos Sánchez de Ibarguen
Journal: Annals of Oncology (2020)
1627MO Systemic therapies in advanced epithelioid haemangioendothelioma (EHE): A retrospective international series from the World Sarcoma Network
Authors: A.M. Frezza, V. Ravi, S. Lo Vullo, F. Tolomeo, T. Wei-Wu Chen, P. Teterycz, G.G. Baldi, A. Italiano, N. Penel, A. Brunello, F. Duffaud, N. Hindi, S. Iwata, A. Smrke, A. Fedenko, H. Gelderblom, W. Van Der Graaf, A. Vozy, B. Vincenzi, S. Stacchiotti
Journal: Annals of Oncology (2020)
Enabling precision rehabilitation interventions using wearable sensors and machine learning to track motor recovery
Authors: Catherine Adans-Dester, Nicolas Hankov, Anne O’Brien, Gloria Vergara-Diaz, Randie Black-Schaffer, Ross Zafonte, Jennifer Dy, Sunghoon I. Lee, Paolo Bonato
Journal: npj Digital Medicine (2020)

The need to develop patient-specific interventions is apparent when one considers that clinical studies often report satisfactory motor gains only in a portion of participants. This observation provides the foundation for "precision rehabilitation". Tracking and predicting outcomes defining the recovery trajectory is key in this context. Data collected using wearable sensors provide clinicians with the opportunity to do so with little burden on clinicians and patients. The approach proposed in this paper relies on machine learning-based algorithms to derive clinical score estimates from wearable sensor data collected during functional motor tasks. Sensor-based score estimates showed strong agreement with those generated by clinicians. Score estimates of upper-limb impairment severity and movement quality were marked by a coefficient of determination of 0.86 and 0.79, respectively. The application of the proposed approach to monitoring patients' responsiveness to rehabilitation is expected to contribute to the development of patient-specific interventions, aiming to maximize motor gains.
ERCP during the COVID-19 epidemic
Authors: Hongling Wang, Yafei Zhang, Lan Liu, Xiaodan Zhang, Qiu Zhao
Journal: Endoscopy (2020)

See also: ERCP in patients with COVID-19 infection – is a single-use duodenoscope the safer option?Endoscopy 2020; 52(10): 932-932DOI: 10.1055/a-1180-8681
1398P Real-life progression (PD) pattern of EGFR mutant advanced non-small cell lung cancer (aNSCLC) patients (pts) receiving systemic therapy after first- or second-generation tyrosine kinase inhibitor (1-2 gen TKI)
Authors: A. Dal Maso, A. Ferro, M. Lorenzi, V. Polo, D. Scattolin, A. Del Conte, E. Scoccia, S. Frega, L. Bonanno, S. Indraccolo, F. Calabrese, V. Guarneri, P.F. Conte, G. Pasello
Journal: Annals of Oncology (2020)
319P Prognosis for patients with oligometastatic breast cancer who achieve NED status after systemic and local therapy
Authors: E. Olcina Aguado, M.T.M. Martinez, J.A. Carbonell-Asins, J. Montón-Bueno, B. Ortega, J. Poveda, M. Tapia, S. Moragón, C. Hernando Melia, L. Candia, S. Simon, A. Adam-Artigues, I. Garrido-Cano, B. Pattanayak, E. Tormo, P. Eroles, A. Lluch, B. Bermejo De Las Heras, J.M. Cejalvo
Journal: Annals of Oncology (2020)
1171P Genetic characteristics of neuroendocrine tumours at different anatomical sites
Authors: H. Zhao, Y. Chi, W. Liu, L. Zuo, Y. Wang, W. Cai, S. Shi, B. Zheng, Y. Ge, R. Li, L. Song, Y. Yang, Z. Liu, X. Dou
Journal: Annals of Oncology (2020)
Development, validation, and implementation of biomarker testing in cardiovascular medicine state-of-the-art: proceedings of the European Society of Cardiology—Cardiovascular Round Table
Authors: Perry Elliott, Martin R Cowie, Jennifer Franke, André Ziegler, Charalambos Antoniades, Jeroen Bax, Chiara Bucciarelli-Ducci, Frank A Flachskampf, Christian Hamm, Magnus T Jensen, Hugo Katus, Alan Maisel, Theresa McDonagh, Clemens Mittmann, Pieter Muntendam, Eike Nagel, Giuseppe Rosano, Raphael Twerenbold, Faiez Zannad
Journal: Cardiovascular Research (2020)

Many biomarkers that could be used to assess ejection fraction, heart failure, or myocardial infarction fail to translate into clinical practice because they lack essential performance characteristics or fail to meet regulatory standards for approval. Despite their potential, new technologies have added to the complexities of successful translation into clinical practice. Biomarker discovery and implementation require a standardized approach that includes: identification of a clinical need; identification of a valid surrogate biomarker; stepwise assay refinement, demonstration of superiority over current standard-of-care; development and understanding of a clinical pathway; and demonstration of real-world performance. Successful biomarkers should improve efficacy or safety of treatment, while being practical at a realistic cost. Everyone involved in cardiovascular healthcare, including researchers, clinicians, and industry partners, are important stakeholders in facilitating the development and implementation of biomarkers. This article provides suggestions for a development pathway for new biomarkers, discusses regulatory issues and challenges, and suggestions for accelerating the pathway to improve patient outcomes. Real-life examples of successful biomarkers-high-sensitivity cardiac troponin, T2* cardiovascular magnetic resonance imaging, and echocardiography-are used to illustrate the value of a standardized development pathway in the translation of concepts into routine clinical practice.
Covid-19: The fatal attraction of herd immunity
Authors: Kamran Abbasi
Journal: BMJ (2020)

Volatility in general, and VIX in particular, is widely thought to influence hedge fund returns. This article shows that not only is VIX negatively correlated to hedge fund returns, the correlation profile is asymmetric with the correlation being more negative in negative months for hedge funds. When hedge funds are delivering the worst quartile returns, the diversification benefit is best. Equally interestingly, when the diversification or protection is least needed, i.e. in highest quartile months, the correlation is positive. It is explored whether a small allocation to VIX can be constructively used for risk reduction or downside protection in broad based hedge fund portfolios. Standard mean variance measures suggest a static allocation of 0% to 10%, which is consistent with the common sense approach of allocation only a very small portion of the portfolio to volatility. This range, together with the mean reverting property of VIX, and the asymmetric correlation of VIX and hedge fund returns is used to explore a tactical allocation strategy that outperforms a simple static allocation of VIX or a portfolio with no VIX allocation on a risk adjusted basis, while reducing downside risks.
CN13 Leadership in support of interprofessional collaboration in the FICAN West Cancer Centre
Authors: V. Sulosaari, H. Kuusisto, M. Rekunen, P. Rautava, M. Siekkinen, L. Seppänen, M. Stolt, T. Vahlberg, L. Walta, H. Leino-Kilpi
Journal: Annals of Oncology (2020)
1710P International multicentric evaluation of breast cancer patients’ satisfaction and experience with oncology telemedicine visits (TV) during the COVID-19 outbreak
Authors: A. Bizot, P-E. Heudel, M. Karimi, C. Levy, L. Vanlemmens, C. Uzan, E. Deluche, D. Genet, M. Saghatchian, S. Giacchetti, J. Grenier, A. Patsouris, V.C. Dieras, J-Y. Pierga, T. Petit, S. Ladoire, W. Jacot, S. Delaloge, M. Lambertini, B. Pistilli
Journal: Annals of Oncology (2020)
1133P Skin photoaging around the site of occurrence of primary melanoma as a clinical predictive biomarker of response to PD-1 inhibitors
Authors: D. Russo, F. Poizeau, M. Dinulescu, R. Baggio, C. Orion, C. Soethoudt, S. Law Ping Man, C. Saillard, M. Pracht, T. Lesimple, A. Dupuy, L. Boussemart
Journal: Annals of Oncology (2020)
474P Prognostic and predictive role of Consensus Molecular Subtypes (CMS) determined by immunohistochemistry in metastatic colorectal cancer (mCRC)
Authors: O. Higuera Gomez, V. Heredia Soto, I. Machado, M.C. Mendez, M. Cuatrecasas, C. Horndler, L. Vermeulen, S. Ten Hoorn, M. Mendiola, M. Martín-Richard, A. Ruiz-Casado, E. Galvez, J. Aparicio, I. Sevilla García, R. Leno, C. Fernández-Martos, V. Alonso-Orduna, A. Fernandez Montes, J. Maurel, J. Feliu
Journal: Annals of Oncology (2020)
Sex-Specific Selection Drives the Evolution of Alternative Splicing in Birds
Authors: Thea F Rogers, Daniela H Palmer, Alison E Wright
Journal: Molecular Biology and Evolution (2020)

Males and females of the same species share the majority of their genomes, yet they are frequently exposed to conflicting selection pressures. Gene regulation is widely assumed to resolve these conflicting sex-specific selection pressures, and although there has been considerable focus on elucidating the role of gene expression level in sex-specific adaptation, other regulatory mechanisms have been overlooked. Alternative splicing enables different transcripts to be generated from the same gene, meaning that exons which have sex-specific beneficial effects can in theory be retained in the gene product, whereas exons with detrimental effects can be skipped. However, at present, little is known about how sex-specific selection acts on broad patterns of alternative splicing. Here, we investigate alternative splicing across males and females of multiple bird species. We identify hundreds of genes that have sex-specific patterns of splicing and establish that sex differences in splicing are correlated with phenotypic sex differences. Additionally, we find that alternatively spliced genes have evolved rapidly as a result of sex-specific selection and suggest that sex differences in splicing offer another route to sex-specific adaptation when gene expression level changes are limited by functional constraints. Overall, our results shed light on how a diverse transcriptional framework can give rise to the evolution of phenotypic sexual dimorphism.
LBA72 Assessment of clinical and laboratory prognostic factors in patients with cancer and SARS-CoV-2 infection: The COVID-19 and Cancer Consortium (CCC19)
Authors: P. Grivas, J. Warner, Y. Shyr, D. Shah, S.M. Rubinstein, N.M. Kuderer, T.K. Choueiri, D. Rivera, C. Painter, M.A. Thompson, S. Peters, A. Desai, A.R. Khaki, N.A. Pennell, J. Hawley, B. Halmos, M.M. Puc, G.H. Lyman, B.I. Rini, G. Lopes
Journal: Annals of Oncology (2020)
1226P Curative treatment in EGFR mt+ NSCLC stage III by induction TKI-chemotherapy combination: Feasibility and outcome in 7 cases
Authors: L. Heukamp, J. Roeper, M. Falk, B. Kah, M. Tiemann, D. Scriba, R. Prenzel, K. Willborn, F. Griesinger
Journal: Annals of Oncology (2020)
Metagenomic analysis reveals distinct patterns of gut lactobacillus prevalence, abundance, and geographical variation in health and disease
Authors: Tarini Shankar Ghosh, Jerome Arnoux, Paul W. O’Toole
Journal: Gut Microbes (2020)

Lactobacilli are exploited extensively for food fermentation and biotechnology. Some food and gut isolates have been developed as probiotics, for which species that may be commensal to the human host are considered desirable. However, the robustness of defining original niches for lactobacilli - food, environment, the gut - is questionable, and culture-independent analyses of prevalence in different human populations is lacking. Here we analyzed the abundance of lactobacilli in 6,154 subjects from a database of highly curated fecal shotgun metagenomics data spanning 25 nationalities, with ages ranging from infancy to 102 years. Twenty-five species were detected, which we assigned into low, medium, and high prevalence groups. The microbiome of apparently healthy individuals could be categorized into 6 clusters or Lactobacillotypes (LbTypes), with three of the Lbtypes being dominated by L. delbrueckii, L. ruminis, L. casei, and the other three comprising a combination of different species. These Lactobacillus clusters exhibit distinct global abundance patterns. The cluster prevalences also display distinct age-specific trends influenced by geography, with overall lactobacillus prevalence increasing significantly with age in North America and Europe but declining with age in non-Westernized societies. Regression analysis stratified by regional location identified distinct associations of the Lactobacillotypes with age, BMI, and gender. Cirrhosis, fatty-liver, , IBD and T2D were characterized by net gain of lactobacilli, whereas hypertension patients harbored depleted lactobacillus levels. Collectively these data indicate that the species abundance of gut lactobacilli is moderated by geography, diet, and interaction with the whole microbiome, and has strong interactions with diseases associated with a western lifestyle.
TRP Channel Cooperation for Nociception: Therapeutic Opportunities
Authors: Dorien Bamps, Joris Vriens, Jan de Hoon, Thomas Voets
Journal: The Annual Review of Pharmacology and Toxicology (2020)

Chronic pain treatment remains a sore challenge, and in our aging society, the number of patients reporting inadequate pain relief continues to grow. Current treatment options all have their drawbacks, including limited efficacy and the propensity of abuse and addiction; the latter is exemplified by the ongoing opioid crisis. Extensive research in the last few decades has focused on mechanisms underlying chronic pain states, thereby producing attractive opportunities for novel, effective and safe pharmaceutical interventions. Members of the transient receptor potential (TRP) ion channel family represent innovative targets to tackle pain sensation at the root. Three TRP channels, TRPV1, TRPM3, and TRPA1, are of particular interest, as they were identified as sensors of chemical- and heat-induced pain in nociceptor neurons. This review summarizes the knowledge regarding TRP channel–based pain therapies, including the bumpy road of the clinical development of TRPV1 antagonists, the current status of TRPA1 antagonists, and the future potential of targeting TRPM3.
Redefining Left Ventricular Assist Device Indications and Strategies
Authors: Nirvik Pal, Mark Nelson, John Butterworth
Journal: JAMA Cardiology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
1365P A prospective, phase II trial of low-dose afatinib monotherapy for patients with EGFR, mutation-positive, non-small cell lung cancer (TORG1632)
Authors: R. Noro, S. Igawa, A. Bessho, T. Hirose, S. Tsuneo, M. Nakashima, K. MInato, N. Seki, T. Tokito, T. Harada, S. Sasada, S. Miyamoto, Y. Tanaka, N. Furuya, T. Kaburagi, H. Hayashi, H. Iihara, K. Naoki, H. Okamoto, K. Kubota
Journal: Annals of Oncology (2020)
Human Retinal Microvasculature‐on‐a‐Chip for Drug Discovery
Authors: Héloïse Ragelle, Karen Dernick, Sonia Khemais, Cordula Keppler, Lucien Cousin, Yohan Farouz, Chris Louche, Sascha Fauser, Stefan Kustermann, Mark W. Tibbitt, Peter D. Westenskow
Journal: Advanced Healthcare Materials (2020)

Abstract Retinal cells within neurovascular units generate the blood–retinal barrier (BRB) to regulate the local retinal microenvironment and to limit access to inflammatory cells. Breakdown of the endothelial junctional complexes in the BRB negatively affects neuronal signaling and ultimately causes vision loss. As new therapeutics are being developed either to prevent barrier disruption or to restore barrier function, access to physiologically relevant human in vitro tissue models that recapitulate important features of barrier biology is essential for disease modeling, target validation, and toxicity assessment. Here, a tunable organ‐on‐a‐chip model of the retinal microvasculature using human retinal microvascular endothelial cells with integrated flow is described. Automated imaging and image analysis methods are employed for facile screening of leakage mediators and cytokine inhibitors on barrier properties. The developed retinal microvasculature‐on‐a‐chip will enable improved understanding of BRB biology and provide an additional tool for drug discovery.
1904P Clinical implications of distinct immunoprofiles in patients with thymic epithelial tumours and autoimmunity
Authors: G. Palmieri, M. Giuliano, M. Tortora, P. Formisano, A.M. Malfitano, V. D'Esposito, G. Botti, A.L. Marretta, V. Margherita, V. Di Lauro, B. Daniele, S. De Placido, A. Verde, M. Ottaviano
Journal: Annals of Oncology (2020)
1624MO Weekly nab-paclitaxel for progressive or symptomatic desmoid tumors: A multicenter single arm phase II trial from the Spanish Group for Research on Sarcoma (GEIS)
Authors: J. Martin Broto, N. Hindi, A. Redondo, J.M. Morales, D. Marcilla, C. Valverde, P. Luna, R. Diaz-Beveritge, J. Martinez-Trufero, J.A. Lopez-Martin, V. Martinez, A. Gutierrez, A. Lopez-Pousa
Journal: Annals of Oncology (2020)
1479P Clinicopathological and genomic characteristics of DNA Mismatch Repair-Deficient (dMMR) and microsatellite instability-high (MSI-H) resected gastric adenocarcinoma
Authors: J. Zhou, B. Liang, M. Yin, H. Zhang, F. Liu, L. Dong, B. Zhang, Y. Xu
Journal: Annals of Oncology (2020)
922P EACH: A phase II study evaluating the safety and anti-tumour activity of avelumab and cetuximab in recurrent/metastatic squamous cell carcinomas
Authors: M. Forster, R. Metcalf, J. Sacco, A. Kong, G. Wheeler, S. Forsyth, R. Bhat, K. Blair, J. Ward, H. Lowe, V. Spanswick, L. Ensell, J. Hartley, L. White
Journal: Annals of Oncology (2020)
1361P Determination of ALK rearrangements in non-small cell lung cancer: Clinical and economic impact of current practice in Spain
Authors: L. Cabezón Gutiérrez, H. Torres, E. Nadal, D. Bautista, A.L. Ortega Granados, F. Rojo Todo, L. Ruiz De Alda, F. Garcia, P. Vieitez, D. Carcedo
Journal: Annals of Oncology (2020)